Pfizer: collaboration with Clear Creek Bio against Covid

(CercleFinance.com) - Pfizer and Clear Creek Bio today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential SARS-CoV-2 papain-like protease (PLpro) inhibitors for the oral treatment of COVID-19.


Under the terms of the agreement, both companies will work together to identify a PLpro candidate to advance into the clinic, with Pfizer then having sole responsibility for development and commercialisation activities.

This program will expand Pfizer's pipeline of innovative anti-infectives and, if successful, will complement Pfizer's current portfolio of COVID-19 products with direct-acting antiviral agents against various SARS-CoV-2 targets.

It is critical that we stay ahead of the virus by continuing to advance clinical development opportunities, as well as innovating through our internal programs and partnerships, Pfizer said,.


Copyright (c) 2022 CercleFinance.com. All rights reserved.